

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	REVA Medical, Inc.
ARBN	146 505 777

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr. Ross A. Breckenridge
Date of last notice	8 June 2017

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
Date of change	10 July 2017
No. of securities held prior to change	<ul style="list-style-type: none"> • 27,730 CDIs (equivalent to 2,773 shares of common stock) • 21,300 shares of common stock (equivalent to 213,000 CDIs) • 30,000 options, each to acquire 1 share of common stock at an exercise price of US\$3.90 per share, under the Company's Amended and Restated 2010 Equity Incentive Plan • 11,800 options each to acquire 1 share of common stock at an exercise price of US\$8.30 per share, under the Company's Amended and Restated 2010 Equity Incentive Plan
Class	<ul style="list-style-type: none"> • CDIs (27,730 CDIs) • Common stock (21,300 shares of common stock)(equivalent to 213,000 CDIs) • Options (over 41,800 shares) (equivalent to 418,000 CDIs)
Number acquired	<ul style="list-style-type: none"> • 10,500 options, each to acquire 1 share of common stock at an exercise price of US\$6.45 per share, under the Company's Amended and Restated 2010 Equity Incentive Plan • 6,000 restricted stock units, each for 1 share of common stock upon vesting, under the Company's Amended and Restated 2010 Equity Incentive Plan

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y Change of Director's Interest Notice

Number disposed	None
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	None
No. of securities held after change	<ul style="list-style-type: none"> • 27,730 CDIs (equivalent to 2,773 shares of common stock) • 21,300 shares of common stock (equivalent to 213,000 CDIs) • 30,000 options, each to acquire 1 share of common stock at an exercise price of US\$3.90 per share, under the Company's Amended and Restated 2010 Equity Incentive Plan • 11,800 options each to acquire 1 share of common stock at an exercise price of US\$8.30 per share, under the Company's Amended and Restated 2010 Equity Incentive Plan • 10,500 options each to acquire 1 share of common stock at an exercise price of US\$6.45 per share, under the Company's Amended and Restated 2010 Equity Incentive Plan • 6,000 restricted stock units, each for 1 share of common stock upon vesting, under the Company's Amended and Restated 2010 Equity Incentive Plan
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	<ul style="list-style-type: none"> • Grant of options to purchase common stock • Award of restricted stock units for common stock

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

For personal use only